<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Disease prodromal stage &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/disease-prodromal-stage/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Thu, 28 May 2026 11:28:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Disease prodromal stage &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study of serotonin system changes in early Parkinson&#8217;s disease using [11C]DASB and [11C]SB207145 PET imaging in people with SNCA gene mutations</title>
		<link>https://clinicaltrials.eu/trial/study-of-serotonin-system-changes-in-early-parkinsons-disease-using-11cdasb-and-11csb207145-pet-imaging-in-people-with-snca-gene-mutations/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:06:22 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-of-serotonin-system-changes-in-early-parkinsons-disease-using-11cdasb-and-11csb207145-pet-imaging-in-people-with-snca-gene-mutations/</guid>

					<description><![CDATA[This study focuses on Parkinson&#8217;s disease, specifically examining its early stage known as the prodromal phase. The research uses two special imaging substances: 11C-DASB and 11C-SB207145, which are given as solutions for injection into the bloodstream. These substances help create detailed images of the brain using a special scanning technique called PET (Positron Emission Tomography). [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This study focuses on <b>Parkinson&#8217;s disease</b>, specifically examining its early stage known as the <b>prodromal phase</b>. The research uses two special imaging substances: <b>11C-DASB</b> and <b>11C-SB207145</b>, which are given as solutions for injection into the bloodstream. These substances help create detailed images of the brain using a special scanning technique called <b>PET</b> (Positron Emission Tomography).</p>
<p>The purpose of this study is to investigate changes in the brain&#8217;s serotonin system during the early stages of Parkinson&#8217;s disease. The research specifically looks at people who carry a particular genetic change in the <b>SNCA gene</b>, which is associated with Parkinson&#8217;s disease. The study will compare these individuals with healthy people who do not have this genetic change.</p>
<p>During the study, participants will receive the imaging substances through an <b>intravenous</b> injection. They will undergo brain scanning procedures that include <b>MRI</b> (Magnetic Resonance Imaging) and other specialized imaging tests. The study will examine how these substances bind to specific areas in the brain and what this reveals about the early stages of the disease.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
